A 5- year randomized, double-blind, placebo-controlled, multi-center study assessing the efficacy, safety, and tolerability of intra-articular regimens of LNA043 versus placebo in patients with symptomatic knee osteoarthritis (ONWARDS)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509937-37-00

Acronym

CLNA043A12202

Enrollment

250

Registered

2024-05-16

Start date

2021-07-21

Completion date

2025-05-27

Last updated

2024-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Brief summary

Change from baseline in the knee structure

Detailed description

Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function, Change from baseline in cartilage structure, Change from baseline in physical function, Proportion of participants demonstrating structural progression, Assessing adverse events and serious adverse events

Interventions

DRUGLNA043

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline in the knee structure	—

Secondary

Measure	Time frame
Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function, Change from baseline in cartilage structure, Change from baseline in physical function, Proportion of participants demonstrating structural progression, Assessing adverse events and serious adverse events	—

Measure

Time frame

—

Countries

Czechia, Denmark, Estonia, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026